Literature DB >> 33758616

MRPL42 is activated by YY1 to promote lung adenocarcinoma progression.

Wei Jiang1, Chengpeng Zhang1, Yunteng Kang1, Xiaojun Yu1, Pei Pang2, Guangbin Li1, Yu Feng1.   

Abstract

Mammalian mitochondrial ribosomal proteins are a group of protein factors encoded by nuclear genes, responsible for the synthesis of proteins in mitochondria. As a member of mitochondrial ribosomal proteins, MRPL42 (mitochondrial ribosomal protein L42) belongs to 28S and 39S subunits. The current literature showed that its role in lung adenocarcinoma (LUAD) was not clear. We found that MRPL42 was highly expressed in early-stage LUAD tissues and cell lines, and remarkably related to the prognosis of patients. Knockdown of MRPL42 could reduce the proliferation and colonization, promote cell cycle arrest in G1/S phase, and weaken the migration and invasion ability of LUAD cells in vitro. Moreover, depletion of MRPL42 also inhibited tumor growth in vivo. Bioinformatics analysis found that YY1 may bind to the promoter region upstream of the MRPL42 gene to promote the transcription of MRPL42, which was verified by the ChIP and Dual luciferase reporter assay. QRT-PCR confirmed that knocking down YY1 could attenuate the expression of MRPL42. In summary, MRPL42 acts as an oncogene in LUAD, and its expression level is regulated by YY1. © The author(s).

Entities:  

Keywords:  MRPL42; YY1; metastasis; proliferation; transcriptional regulation

Year:  2021        PMID: 33758616      PMCID: PMC7974901          DOI: 10.7150/jca.52277

Source DB:  PubMed          Journal:  J Cancer        ISSN: 1837-9664            Impact factor:   4.207


  4 in total

Review 1.  Potential of Mitochondrial Ribosomal Genes as Cancer Biomarkers Demonstrated by Bioinformatics Results.

Authors:  Shunchao Bao; Xinyu Wang; Mo Li; Zhao Gao; Dongdong Zheng; Dihan Shen; Linlin Liu
Journal:  Front Oncol       Date:  2022-05-26       Impact factor: 5.738

2.  Computational Analyses of YY1 and Its Target RKIP Reveal Their Diagnostic and Prognostic Roles in Lung Cancer.

Authors:  Silvia Vivarelli; Luca Falzone; Caterina Maria Grillo; Benjamin Bonavida; Claudia Crimi; Ignazio La Mantia; Massimo Libra
Journal:  Cancers (Basel)       Date:  2022-02-12       Impact factor: 6.639

3.  Identification of the Upregulation of MRPL13 as a Novel Prognostic Marker Associated with Overall Survival Time and Immunotherapy Response in Breast Cancer.

Authors:  Hongshan Ye; Ning Zhang
Journal:  Comput Math Methods Med       Date:  2021-11-25       Impact factor: 2.238

4.  TNF-α Induced Myotube Atrophy in C2C12 Cell Line Uncovers Putative Inflammatory-Related lncRNAs Mediating Muscle Wasting.

Authors:  Tomasz Powrózek; Dominika Pigoń-Zając; Marcin Mazurek; Michael Ochieng Otieno; Mansur Rahnama-Hezavah; Teresa Małecka-Massalska
Journal:  Int J Mol Sci       Date:  2022-03-31       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.